Cytodyn Inc (CYDY)

[Midasbro]

The MOST important aspect...

Of the press release is that it only involves the US market!

In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera will also make an investment in CytoDyn of $4 million in the form of registered CytoDyn common stock

————————

Poised to reach over US$10.4 Billion by the year 2025, Multi-Class Combination Drugs will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 2.8% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$229.7 Million to the region's size and clout in the next 5 to 6 years. Over US$185.9 Million worth of projected demand in the region will come from the rest of the European markets. In Japan, Multi-Class Combination Drugs will reach a market size of US$549.9 Million by the close of the analysis period.

As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 5.7% over the next couple of years and add approximately US$1.8 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

https://www.ptcommunity.com/wire/global-hiv-drugs-market-report-2019-2025-market-projected-grow-63-billion